Celgene Corp. (CELG) Falls 2.87% for January 04

Equities Staff |

One of the S&P 500’s big losers for Monday January 04 was Celgene Corp. (CELG). The company’s stock fell 2.87% to $116.32 on volume of 3.65 million shares.

The stock opened the day at 116.77 and traded between a low of $116.10 and a high of $118.43. The stock finished the day down $3.4375 per share. Celgene Corp. has an average daily volume of 5.2 million and a total float of 785.65 million shares. The 50-day SMA for Celgene Corp. is $115.56 and its 200-day SMA is $118.18. The high for the stock over the last 52 weeks is $140.72 and the low is $92.98.

Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corp. is centered in Summit, NJ, and has 6,012 employees. Today’s trading day leaves the company with a market cap of $91.39 billionwith a P/E Ratio of 60.5. The company has a P/S ratio of 14.06, P/B ratio of 17.01, and a -14.9.

For a complete fundamental analysis analysis of Celgene Corp., check out Equities.com’s Stock Valuation Analysis report for CELG. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…